Ablynx

@AblynxABLX

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® for a range of serious human diseases.

Ghent/Zwijnaarde, Belgium
ablynx.com
2012(e)ko maiatzak(e)tik Twitterren
5 Argazki edo bideo Argazkiak eta bideoak

Txioak

You blocked @AblynxABLX

Are you sure you want to view these Tweets? Viewing Tweets won't unblock @AblynxABLX

  1. (e)k Bertxiotua
    uzt. 26

    FDA designates top nanobody caplacizumab fast track designation: 6-10 months faster approval

    3 bertxio 4 atsegin
  2. (e)k Bertxiotua
    uzt. 20

    2.4bn "bioeuro": Belgian Nanobody delights now also tasteful in France

    2 bertxio 7 atsegin
  3. uzt. 20

    and Sanofi to develop up to 8 Nanobody®-based therapeutics focused on immuno-inflammatory diseases

    Erantzun 1 9 bertxio 14 atsegin
  4. eka. 27

    achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc.

    7 bertxio 16 atsegin
  5. eka. 26

    initiates a single and multiple dose Phase I study of caplacizumab in healthy Japanese subjects

    4 bertxio 6 atsegin
  6. mai. 29

    launches , a new website dedicated to Thrombotic Thrombocytopenic Purpura (TTP)

    10 bertxio 9 atsegin
  7. mai. 22

    receives €15M milestone from Merck KGaA for novel Nanobody in osteoarthritis

    10 bertxio 12 atsegin
  8. mai. 18

    Meet our experts and recruiters (booth 99) @

    2 atsegin
  9. mai. 11

    Ablynx zit op schema via

    4 bertxio 6 atsegin
  10. mai. 11

    Q1 2017 "Positive start of the year; good progress in multiple programmes; strong cash position"

    6 bertxio 4 atsegin
  11. mai. 10

    Publication in Journal of Thrombosis and Haemostasis "Caplacizumab reduces major thromboembolic events"

    7 bertxio 7 atsegin
  12. mai. 2

    successfully completes patient recruitment in its Phase III Hercules study of caplacizumab

    2 bertxio 6 atsegin
  13. api. 7

    Annual Report 2016 is available online - view via

    Bertxio 1 4 atsegin
  14. api. 7

    - Adrianus van Herk (aandeelhouder Ablynx): 'België en Nederland zijn wereldtop' via @trends

    Bertxio 1 4 atsegin
  15. (e)k Bertxiotua
    mar. 6

    Compelling data for developed psoriasis nanobody in collaboration

    3 bertxio 2 atsegin
  16. (e)k Bertxiotua
    ots. 28

    Good morning to those waking up in Europe, Africa and the Middle East! Share with us what you have planned for today!

    15 erantzun 51 bertxio 103 atsegin
  17. (e)k Bertxiotua
    ots. 24

    you will find out that is dedicated to creating new medicines which will make a real difference to society!

    Bertxio 1 Atsegin 1
  18. ots. 23

    FYR 2016: significant progress in R&D pipeline; strong cash position; major catalysts in 2017.

    4 bertxio 3 atsegin
  19. ots. 9

    will present additional data from the Phase IIb RA combination study of vobarilizumab at the Annual CRA Meeting

    2 bertxio 2 atsegin
  20. ots. 6

    Ablynx files caplacizumab for ultra rare blood disorder
    6 bertxio 9 atsegin

@AblynxABLX(e)k ez du oraindik Txiokatu

Badirudi kargak luze hartuko duela.

Baliteke Twitterren kapazitatez gaindi egotea edo momentuko gainkarga bat izatea. Berriro saiatu edo Twitterren Egoera ikusi informazio gehiagorako.

    Agian hau ere gustuko duzu

    ·